Electrophysiological features and prognosis of Guillain-Barré syndrome in Israel: A single-center's 20 years' experience

J Neurol Sci. 2020 Oct 15:417:117074. doi: 10.1016/j.jns.2020.117074. Epub 2020 Aug 1.

Abstract

Introduction: We previously reported on 40 patients with Guillain-Barré syndrome (GBS) identified 1999-2005 at our center, and showed that a higher proportion had an axonal pattern, compared to Europe and North America.

Methods: Retrospective chart review of 100 adult patients with GBS between 2006 and 2018 at Shamir Medical Center.

Results: 46.8% of those with an abnormal EMG had an axonal pattern. Of the 60 patients who presented with mild disease (defined as Hughes score 1-2), walking deteriorated in 35 (58%, considering any worsening of Hughes score). 20 patients (33%) lost the ability to walk independently (Hughes score 3), 8 reached a point they could not walk (Hughes 4), and 2 needed mechanical ventilation. Ninety-four of 100 patients (94%) were treated with intravenous immunoglobulins (IVIg). Using ECG monitoring and DVT prophylaxis, IVIg-related adverse reactions were rare.

Conclusions: This study demonstrated a higher proportion of axonal GBS patients in Israel, compared to European and North American patients, replicating the findings in the 1999-2005 patients. Due to the progressive nature of the disease, with more than half of patients presenting with mild disease deteriorating and needing inpatient rehabilitation - we advocate initiation of treatment once a clinical diagnosis of GBS is made.

Keywords: Axonal variant; Demyelinating variant; GBS; IVIg safety; Outcomes.

MeSH terms

  • Adult
  • Europe
  • Guillain-Barre Syndrome* / diagnosis
  • Guillain-Barre Syndrome* / epidemiology
  • Guillain-Barre Syndrome* / therapy
  • Humans
  • Immunoglobulins, Intravenous / therapeutic use
  • Israel / epidemiology
  • North America
  • Prognosis
  • Retrospective Studies

Substances

  • Immunoglobulins, Intravenous